Dr. Reddy's Laboratories Limited (RDY) Down 7.8% — Time to Exit?
Dr. Reddy's Laboratories Limited (RDY) suffered one of its steeper single-session declines in recent memory, shedding $0.98 to close at $11.58 on the NYSE. The drop pulled shares to their lowest levels since the 52-week high of $15.67 reached on June 26, 2026 — a level now sitting 26.1% above the current price, underscoring just how quickly sentiment has deteriorated over the past month.
Trading volume came in at approximately 783,000 shares, a fraction of the 90-day average of roughly 2.5 million. The sharply below-average turnover suggests the session's damage was concentrated rather than panic-driven, though the price action was unambiguous in its direction. Light volume on a significant down day does little to inspire confidence in an immediate recovery.
Why Dr. Reddy's Laboratories Limited Price is Moving Lower
The session's selloff was triggered by a deeply disappointing Q1 FY27 earnings report that left little room for optimism. Consolidated profit attributable to shareholders collapsed 68.7% year over year to just ₹443.5 crore, falling far short of analysts' ₹722 crore estimate. Revenue declined 5.6% to ₹8,070.5 crore, also missing the ₹8,220.6 crore consensus. Reported EPS landed at ₹5.33, or approximately $0.06 per ADS, against a consensus estimate of $0.0927 — a miss of roughly 35% that removed any ambiguity about the quarter's severity. EBITDA dropped 55.7% to ₹1,008.8 crore, and the EBITDA margin compressed dramatically to 12.5% from 26.7% a year earlier, signaling that cost pressures hit the business across multiple layers simultaneously.
The single largest driver of the North American revenue collapse was the fading contribution from lenalidomide, a blockbuster generic that had previously inflated results. North American revenue plunged 35.4% to ₹2,204.8 crore as that tailwind reversed sharply. Compounding the pain, Dr. Reddy's booked a ₹239.7 crore provision after semaglutide batches failed quality specifications due to an active-ingredient impurity — an episode management acknowledged knocked approximately 3 percentage points off gross-profit, EBITDA, and pre-tax margins. Gross margin consequently fell to 46.5% from 56.9%, a deterioration that illustrated how vulnerable the company's near-term profitability has become. With North America representing roughly 27% of quarterly revenue, both the earnings collapse and the exposure to that geography are registering as material risks in investors' eyes.
The macro backdrop offered no relief. President Trump's announcement of a tiered tariff framework — zero tariffs on U.S. generic-drug imports through August 1, 2028, followed by 100% tariffs through July 2029 and 200% thereafter — added a longer-term structural threat to an already bruised story. For a company with significant and growing U.S. generic exposure, the tariff trajectory creates genuine uncertainty around future pricing power and margin sustainability. The combination of a severe earnings miss, a product quality failure, and a deteriorating policy environment gave sellers every reason to reduce exposure on July 22.
What is the Dr. Reddy's Laboratories Limited Rating - Should I Sell?
Weiss Ratings assigns RDY a C rating. Current recommendation is Hold.
The C rating captures a business at a genuine crossroads — one where balance sheet discipline and operational efficiency coexist uncomfortably with weakening growth and deteriorating near-term returns. On the positive side, an ROE of 12.16% earns the Excellent Efficiency Index, a respectable figure for a global generics manufacturer competing across multiple geographies and therapeutic categories with significant R&D overhead. The Excellent Solvency Index adds further reassurance that the balance sheet is not itself a source of risk, providing some downside protection even as earnings come under pressure.
The challenges, however, are hard to look past. Revenue growth of -19.13% earns only the Weak Growth Index — and today's earnings report underscores that this is not a temporary blip. The lenalidomide cliff was known, but the semaglutide quality provision and the broader EBITDA implosion suggest that the replacement pipeline has yet to fill the gap. A profit margin of 12.94% is functional but represents a shadow of the profitability the company was generating just a year ago when EBITDA margins were running above 26%. The Weak Total Return Index reflects the cumulative damage that declining fundamentals have inflicted on shareholders, and the Weak Volatility Index is a candid acknowledgment that this stock carries meaningful price risk — a characteristic the July 22 session illustrated vividly. A forward P/E of 21.38 is not excessive in absolute terms, but paying a market-like multiple for a business with negative revenue growth and a collapsing earnings trend demands a clear and credible recovery thesis.
Within the Health Care sector, RDY is on equal footing with AbbVie Inc. (ABBV, C), Merck & Co., Inc. (MRK, C), Thermo Fisher Scientific Inc. (TMO, C), and Pfizer Inc. (PFE, C) — names that carry their own headwinds but generally offer more diversified revenue streams and deeper competitive moats. Danaher Corporation (DHR, C-) ranks below RDY on the Weiss scale, though that distinction provides limited comfort given the pressure Dr. Reddy's faces in the near term. The Hold recommendation reflects a situation where the risk of acting too early in either direction is real: the stock may be oversold relative to longer-term intrinsic value, but the fundamental catalysts needed to justify accumulation are not yet visible.
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (RDY) is a Health Care company with a global footprint spanning generic drug manufacturing, branded formulations, active pharmaceutical ingredients, and biosimilars. Founded in India and headquartered in Hyderabad, the company has built a vertically integrated model that stretches from chemistry and process development through finished-dosage manufacturing and into commercial distribution — giving it cost advantages relative to peers that rely on external API suppliers.
The company's generics business targets high-value, complex molecules in markets including the United States, Europe, and India, where it competes on speed-to-market, regulatory track record, and manufacturing scale. Its proprietary branded portfolio addresses therapeutic categories including cardiovascular, gastrointestinal, and pain management, while its biosimilars pipeline reflects an intentional push into the next generation of off-patent biological therapies. The semaglutide program, despite the quality setback disclosed this quarter, illustrates the kind of high-stakes complex generics bets the company is making to replace lost exclusivity revenue from products like lenalidomide.
Dr. Reddy's also operates a meaningful active pharmaceutical ingredient business that supplies both internal formulation units and third-party customers, providing a degree of vertical integration that helps manage raw material cost volatility. Its manufacturing infrastructure spans multiple FDA-inspected facilities across India, the U.K., and other geographies, and the company holds a substantial portfolio of drug master files and abbreviated new drug applications in the United States. That regulatory capital — built over decades — is a genuine competitive asset, even as near-term execution challenges cloud the earnings picture.
Investor Outlook
Dr. Reddy's Laboratories Limited (RDY) carries a Weiss Rating of C (Hold), a grade that reflects a fundamentally capable business navigating a difficult confluence of pipeline transitions, product quality setbacks, and an increasingly uncertain U.S. tariff environment. Investors should watch whether management can demonstrate meaningful revenue recovery in North America beyond lenalidomide, how quickly the semaglutide quality issue is resolved and production resumes, and whether the proposed U.S. tariff structure forces a strategic rethink of the company's U.S. generics model. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--